DNLI
Price
$16.94
Change
-$0.54 (-3.09%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.48B
102 days until earnings call
Intraday BUY SELL Signals
LITS
Price
$1.77
Change
-$0.16 (-8.29%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
65.11M
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs LITS

Header iconDNLI vs LITS Comparison
Open Charts DNLI vs LITSBanner chart's image
Denali Therapeutics
Price$16.94
Change-$0.54 (-3.09%)
Volume$33.8K
Capitalization2.48B
Lite Strategy
Price$1.77
Change-$0.16 (-8.29%)
Volume$3.08K
Capitalization65.11M
DNLI vs LITS Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
LITS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. LITS commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and LITS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (DNLI: $16.92 vs. LITS: $1.77)
Brand notoriety: DNLI and LITS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 90% vs. LITS: 105%
Market capitalization -- DNLI: $2.48B vs. LITS: $65.11M
DNLI [@Biotechnology] is valued at $2.48B. LITS’s [@Biotechnology] market capitalization is $65.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileLITS’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • LITS’s FA Score: 1 green, 4 red.
According to our system of comparison, LITS is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while LITS’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • LITS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than LITS.

Price Growth

DNLI (@Biotechnology) experienced а -3.42% price change this week, while LITS (@Biotechnology) price change was -11.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.48B) has a higher market cap than LITS($65.1M). DNLI YTD gains are higher at: -16.977 vs. LITS (-28.049).
DNLILITSDNLI / LITS
Capitalization2.48B65.1M3,813%
EBITDA-521.52MN/A-
Gain YTD-16.977-28.04961%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash899MN/A-
Total Debt46.6MN/A-
FUNDAMENTALS RATINGS
DNLI vs LITS: Fundamental Ratings
DNLI
LITS
OUTLOOK RATING
1..100
7479
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
4865
P/E GROWTH RATING
1..100
9929
SEASONALITY SCORE
1..100
5028

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LITS's Valuation (56) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that LITS’s stock grew somewhat faster than DNLI’s over the last 12 months.

LITS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that LITS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as LITS (97) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to LITS’s over the last 12 months.

DNLI's Price Growth Rating (48) in the Biotechnology industry is in the same range as LITS (65) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to LITS’s over the last 12 months.

LITS's P/E Growth Rating (29) in the Pharmaceuticals Other industry is significantly better than the same rating for DNLI (99) in the Biotechnology industry. This means that LITS’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLILITS
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
66%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 10 days ago
73%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 7 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
LITS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AEGOF7.05N/A
N/A
Aegon Ltd.
PCLB31.50N/A
N/A
Pinnacle Bancshares, Inc.
REMYF49.25N/A
N/A
Remy Cointreau SA
MDPEF1.96N/A
N/A
MEDPEER INC.
PRVFF4.17N/A
N/A
PRO REAL ESTATE INVT TR

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-3.20%
NRIX - DNLI
57%
Loosely correlated
+13.09%
RGNX - DNLI
56%
Loosely correlated
-2.84%
ARWR - DNLI
55%
Loosely correlated
-3.71%
OCUL - DNLI
54%
Loosely correlated
+2.81%
BEAM - DNLI
53%
Loosely correlated
-4.24%
More

LITS and

Correlation & Price change

A.I.dvisor indicates that over the last year, LITS has been loosely correlated with GOSS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LITS jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LITS
1D Price
Change %
LITS100%
-8.29%
GOSS - LITS
45%
Loosely correlated
+2.95%
TELO - LITS
29%
Poorly correlated
+0.70%
AXON - LITS
28%
Poorly correlated
-0.50%
DNLI - LITS
27%
Poorly correlated
-3.20%
PMN - LITS
26%
Poorly correlated
+14.38%
More